Such RTK crosstalk has also been observed for the human EGF receptor 2 (HER2), the target of trastuzumab in breast cancer, and preclinical studies indicate synergy with dual IGF-1R/HER2 targeting [122,123]. Here, IGF1R is linked to breast cancer.